Search results for "interquartile range"

showing 10 items of 263 documents

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

2017

Background: Limited data exist regarding the correlation between MRI tumour regression grade (mrTRG) and pathological TRG (pTRG) in rectal cancer. Methods: mrTRG and pTRG were compared in rectal cancer patients from two phase II trials (EXPERT and EXPERT-C). The agreement between radiologist and pathologist was assessed with the weighted κ test while the Kaplan–Meier method was used to estimate survival outcomes. Results: One hundred ninety-one patients were included. Median time from completion of neoadjuvant treatment to pre-operative MRI and surgery was 4.1 weeks (interquartile range (IQR): 3.7–4.7) and 6.6 weeks (IQR: 5.9–7.6), respectively. Fair agreement was found between mrTRG and pT…

MaleCancer ResearchPathologySURGERYColorectal cancerACCURACYmedicine.medical_treatmentMagnetic resonance tumour regression gradePREOPERATIVE CHEMORADIATIONKaplan-Meier EstimateTHERAPY030218 nuclear medicine & medical imaging0302 clinical medicineInterquartile rangeRectal cancerNeoadjuvant therapyAged 80 and overCOMPLETE RESPONSEmedicine.diagnostic_testMiddle AgedMagnetic Resonance ImagingNeoadjuvant TherapyOncology030220 oncology & carcinogenesisFemaleRadiologyLife Sciences & BiomedicineRADIOTHERAPYAdultmedicine.medical_specialtyCytodiagnosismagnetic resonance tumour regression gradeDisease-Free Survival03 medical and health sciencesClinical Trials Phase II as TopicmedicinePathological tumour regression gradeHumansOncology & Carcinogenesisrectal cancerPathologicalpathological tumour regression gradeAgedNeoplasm StagingScience & TechnologyRectal Neoplasmsbusiness.industryTOTAL MESORECTAL EXCISIONMagnetic resonance imagingChemoradiotherapy AdjuvantRANDOMIZED PHASE-IIINEOADJUVANT CHEMORADIOTHERAPYmedicine.diseaseClinical trialRadiation therapyClinical StudyFOLLOW-UPbusiness1112 Oncology And CarcinogenesisChemoradiotherapy
researchProduct

Pulmonary vascular resistance as a potential marker of reactive pulmonary hypertension reduction following sildenafil therapy in patients disqualifie…

2019

Purpose:We sought to determine the predictors of restoration of heart transplantation (HTx) candidacy in pa-tients with systolic heart failure (HF) and reactive fixed pulmonary hypertension (RFPH) defined as pulmonaryvascular resistance (PVR) > 2.5 Wood units (WU), transpulmonary gradient (TPG) > 12 mmHg or ≤2.5 WUwith systolic arterial pressure ≤85 mmHg during vasoreactivity test, following sildenafil therapy.Material and methods:Between2007and20181136patientswereevaluatedatourdepartmentascandidatesforHTx. Thirty-five of them, who presented with systolic HF and were not eligible for HTx due to RFPH, wereincluded in the study (31 men aged 55.1 ± 7.4 years). In all the patients sildenafil wa…

MaleCardiac Catheterizationmedicine.medical_specialtySildenafilHypertension PulmonaryVasodilator Agentsmedicine.medical_treatmentPH reductionSildenafilSildenafil CitratePulmonary hypertension03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineRetrospective StudiesHeart transplantationbusiness.industryVasoreactivity testGeneral MedicineMiddle Agedmedicine.diseasePulmonary hypertensionmedicine.anatomical_structurechemistry030220 oncology & carcinogenesisHeart failureVascular resistanceCardiologyHeart TransplantationFemaleVascular ResistancebusinessBiomarkersAdvances in Medical Sciences
researchProduct

One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients w…

2021

Abstract Introduction and objectives Implementation of a one-step strategy for diagnosis of active Hepatitis C virus (HCV) infection would encourage the early diagnosis and reduce the time to access antiviral treatments. The aim of this study was to evaluate the impact of a HCV one-step diagnosis compared to the traditional two-step protocol in terms of the time required for patients to be seen by specialists and the time taken to start antiviral treatment. Material and methods A comparative study was carried out to assess two diagnostic algorithms (one-step and two-step) for active HCV infection. Serological markers were quantified using the same serum sample to determine both anti-HCV ant…

MaleCare processmedicine.medical_specialtyReferralHepatitis C virusSpecialties of internal medicineViremiaHepacivirusmedicine.disease_causeAntiviral AgentsSerologyMultidisciplinary approachInterquartile rangeInternal medicineHCV-cAgmedicineTelematics referralHumansOne-stepViremiaActive hepatitisHepatologyHepatitis C virusbusiness.industryTwo-stepGeneral MedicineHepatitis C Antibodiesmedicine.diseaseHepatitis CTelemedicineRC581-951FemaleHepatitis C AntigensbusinessAnnals of hepatology
researchProduct

Comparison of Epithor clinical national database and medico-administrative database to identify the influence of case-mix on the estimation of hospit…

2019

BackgroundThe national Epithor database was initiated in 2003 in France. Fifteen years on, a quality assessment of the recorded data seemed necessary. This study examines the completeness of the data recorded in Epithor through a comparison with the French PMSI database, which is the national medico-administrative reference database. The aim of this study was to demonstrate the influence of data quality with respect to identifying 30-day mortality hospital outliers.MethodsWe used each hospital's individual FINESS code to compare the number of pulmonary resections and deaths recorded in Epithor to the figures found in the PMSI. Centers were classified into either the good-quality data (GQD) …

MaleDatabases FactualOutliers DRGPulmonologyCancer Treatment030204 cardiovascular system & hematologyLogistic regressionHealth administration0302 clinical medicineHospital AdministrationInterquartile rangeMedicine and Health SciencesMedicineHospital MortalityRespiratory System ProceduresMultidisciplinaryMortality rateQRRegression analysisHospitals3. Good healthSurgical OncologyOncologyMedicineFemaleRisk AdjustmentLung ResectionResearch ArticleClinical OncologyDeath RatesScienceSurgical and Invasive Medical Procedures03 medical and health sciencesCase mix indexPopulation MetricsHumansDiagnosis-Related GroupsPopulation BiologySurgical Resectionbusiness.industryBiology and Life SciencesModels TheoreticalHealth CareStandardized mortality ratioLogistic ModelsDyspnea030228 respiratory systemHealth Care Facilities[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieData quality[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieClinical MedicinebusinessDemography
researchProduct

Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study.

2019

Aim: To evaluate the changes in renal endpoints in type 2 diabetes patients treated with dapagliflozin versus other glucose-lowering medications in routine clinical practice. Materials and Methods: DARWIN-T2D was a retrospective study conducted at 46 outpatient diabetes clinics in Italy. An automated software collected data on 17 285 patients who received dapagliflozin, glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, or gliclazide, 6751 of whom had a follow-up visit. We analysed changes in albumin excretion rate (AER) and estimated glomerular filtration rate (eGFR). Results: Patients who received dapagliflozin (n = 473) were younger, more obese, and had a poore…

MaleEndocrinology Diabetes and MetabolismType 2 diabetes030204 cardiovascular system & hematologyKidneychemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesRetrospective StudieInterquartile rangeMedicineGliclazideDiabetic NephropathiesDapagliflozinPractice Patterns Physicians'Benzhydryl CompoundAged 80 and overdatabase researchMiddle AgedDiabetes and MetabolismTreatment OutcomeItalyFemaleOriginal Articletype 2 diabetesHumanmedicine.drugGlomerular Filtration Ratemedicine.medical_specialtyGlucosideDrug-Related Side Effects and Adverse ReactionsUrologyRenal function030209 endocrinology & metabolism03 medical and health sciencesDiabetes mellitusantidiabetic drug; dapagliflozin; database research; diabetic nephropathy; type 2 diabetes; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyInternal MedicineHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective Studiesantidiabetic drugtype 2 diabeteCreatinineHypoglycemic Agentbusiness.industrydiabetic nephropathyRetrospective cohort studyBiomarkerOriginal Articlesdapagliflozinmedicine.diseasechemistryDiabetes Mellitus Type 2Diabetic NephropathieDrug-Related Side Effects and Adverse ReactionbusinessBiomarkersDiabetes, obesitymetabolism
researchProduct

Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

2021

BACKGROUND: Immediate initiation of antiretroviral therapy (ART) regardless of CD4 cell count reduces risk for AIDS and non-AIDS-related events in asymptomatic, HIV-positive persons and is the standard of care. However, most HIV-positive persons initiate ART when their CD4 count decreases below 500 × 10 9 cells/L. Consequences of delayed ART on risk for non-AIDS-defining and AIDS-defining cancer, one of the most common reasons for death in HIV, are unclear. OBJECTIVE: To estimate the long-term risk difference for cancer with the immediate ART strategy.DESIGN: Multinational prospective cohort study.SETTING: The D:A:D (Data collection on Adverse events of anti-HIV Drugs) study, which included…

MaleHIV AIDSHIV Infections0302 clinical medicineInterquartile rangeRisk FactorsNeoplasmsMedicine030212 general & internal medicineProspective StudiesProspective cohort study0303 health sciencesIncidenceAbsolute risk reductionDrugsGeneral MedicineMiddle AgedViral LoadAntiretroviral therapy3. Good healthAIDSCancer treatmentPrevention policy and public healthCohortInfectious diseasesCohort studiesFemaleViral loadAdultmedicine.medical_specialtyAnti-HIV AgentsHIV Infections/drug therapySocio-culturaleTime-to-Treatment03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingInternal medicineInternal MedicineHumansAdverse effect030306 microbiologybusiness.industryHIVCancermedicine.diseaseCD4 Lymphocyte CountCancer.Anti-HIV Agents/therapeutic use[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusinessNeoplasms/epidemiologyAnnals of Internal Medicine
researchProduct

Prevalence and prognostic implications of active cytomegalovirus infection in patients with acute heart failure

2010

AHF (acute heart failure) causes significant morbidity and mortality. Recent studies have postulated that the expression of inflammatory mediators, such as cytokines and chemokines, plays an important role in the development and progression of heart failure. A pro-inflammatory state has been postulated as a key factor in triggering CMV (cytomegalovirus) reactivation. Therefore we sought to determine the prevalence of active CMV infection in immunocompetent patients admitted for AHF and to quantify the association with the risk of the combined end point of death or AHF readmission. A total of 132 consecutive patients admitted for AHF were enrolled in the present study. Plasma CMV DNAaemia wa…

MaleHuman cytomegalovirusmedicine.medical_specialtyHeart diseaseCytomegalovirus030204 cardiovascular system & hematologyPatient ReadmissionGastroenterology03 medical and health sciences0302 clinical medicineInterquartile rangeBetaherpesvirinaeInternal medicineHumansMedicineRisk factorAged030304 developmental biologyAged 80 and overHeart Failure0303 health sciencesbiologybusiness.industryProportional hazards modelHazard ratiovirus diseasesGeneral MedicineLength of StayMiddle AgedPrognosismedicine.diseasebiology.organism_classification3. Good healthHeart failureAcute DiseaseCytomegalovirus InfectionsDNA ViralImmunologyMedicineCytokinesFemaleVirus ActivationInflammation MediatorsEpidemiologic MethodsbusinessClinical Science
researchProduct

Cumulative Prognostic Score Predicting Mortality in Patients Older Than 80 Years Admitted to the ICU

2019

OBJECTIVES To develop a scoring system model that predicts mortality within 30 days of admission of patients older than 80 years admitted to intensive care units (ICUs). DESIGN Prospective cohort study. SETTING A total of 306 ICUs from 24 European countries. PARTICIPANTS Older adults admitted to European ICUs (N = 3730; median age = 84 years [interquartile range = 81‐87 y]; 51.8% male). MEASUREMENTS Overall, 24 variables available during ICU admission were included as potential predictive variables. Multivariable logistic regression was used to identify independent predictors of 30‐day mortality. Model sensitivity, specificity, and accuracy were evaluated with receiver operating characteris…

MaleINTENSIVE-CARE-UNITOrgan Dysfunction Scoresmedicine.medical_treatmentPrognosis.MedizinDECISION-MAKINGLogistic regressionlaw.inventionolder adult0302 clinical medicinePHYSICIANSInterquartile rangelaw80 and overMedicine and Health Sciences030212 general & internal medicineHospital MortalityProspective StudiesProspective cohort studyolder adultsAged 80 and overpredictddc:617Respiration[SDV.MHEP.GEG]Life Sciences [q-bio]/Human health and pathology/Geriatry and gerontologyBrief ReportPrognosisIntensive care unitADMISSION3. Good healthEuropeHospitalizationIntensive Care UnitsBrier scoreOlder adultsArtificialFemaleprognosimedicine.medical_specialtycritical care; model; older adults; predict; prognosis; Aged 80 and over; Europe; Female; Hospital Mortality; Hospitalization; Humans; Intensive Care Units; Male; Prospective Studies; Respiration Artificial; Organ Dysfunction Scores; Prognosis03 medical and health sciencesIntensive caremedicineJournal ArticleHumansILL ELDERLY-PATIENTSRenal replacement therapyAgedmodelReceiver operating characteristicbusiness.industry030208 emergency & critical care medicineRespiration Artificialcritical careEmergency medicine[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieBrief ReportsprognosisGeriatrics and Gerontologybusiness
researchProduct

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

2018

It is judged safe to discontinue treatment with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in experimental trials on treatment-free remission (TFR). We collected a total of 293 Italian patients with chronic phase CML who discontinued TKI in deep molecular response. Seventy-two percent of patients were on treatment with imatinib, and 28% with second generation TKI at the time of discontinuation. Median duration of treatment with the last TKI was 77 months [Interquartile Range (IQR) 54;111], median duration of deep molecular response was 46 months (IQR 31;74). Duration of treatment with TKI and duration of deep molecular response were shorter with second generation TK…

MaleImatinib mesylate discontinuation; chronic myelogenous leukemia; treatment-free remission; long-term outcomes; molecular response; cml patients; recommendations; management; dasatinib; cessationchemistry.chemical_compound0302 clinical medicineTreatment Free RemissionPregnancyMED/15 - MALATTIE DEL SANGUEInterquartile rangeingleseMedicinedasatinibChronic Myelogenous Leukemiatreatment-free remissionPonatinibmolecular responseHematologyMiddle AgedProtein-Tyrosine Kinasescml patientsDasatinibTreatment OutcomeLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylateFemaleChronic Myelogenous Leukemia; Discontinuation; Treatment Free Remissionlong-term outcomesmanagementmedicine.drugAdultmedicine.medical_specialtyChronic Myeloid LeukemiaSocio-culturaleDiscontinuationArticletyrosine kinase inhibitors discontinued treatment chronic myeloid leukemia treatment-free remission (TFR)Safety-Based Drug Withdrawals03 medical and health scienceschronic myeloid leukemia tyrosine kinase inhibitors discontinuationMedian follow-upLeukemia Myelogenous Chronic BCR-ABL PositiveInternal medicineImatinib mesylate discontinuationHumansProtein Kinase InhibitorsRetrospective Studiesbusiness.industryImatinibmedicine.diseaseDiscontinuationrespiratory tract diseasesSettore MED/15 - MALATTIE DEL SANGUEcessationNilotinibchemistryrecommendationsbusiness030215 immunologyChronic myelogenous leukemia
researchProduct

Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy : not all AIDS-defining conditions are creat…

2009

Contains fulltext : 80963.pdf (Publisher’s version ) (Open Access) BACKGROUND: The extent to which mortality differs following individual acquired immunodeficiency syndrome (AIDS)-defining events (ADEs) has not been assessed among patients initiating combination antiretroviral therapy. METHODS: We analyzed data from 31,620 patients with no prior ADEs who started combination antiretroviral therapy. Cox proportional hazards models were used to estimate mortality hazard ratios for each ADE that occurred in >50 patients, after stratification by cohort and adjustment for sex, HIV transmission group, number of antiretroviral drugs initiated, regimen, age, date of starting combination antiretrovir…

MaleInfectious diseases and international health [NCEBP 13]Lymphoma030312 virologyEsophageal candidiasisCohort Studies0302 clinical medicineInterquartile range030212 general & internal medicineAIDS-RelatedLymphoma AIDS-Related0303 health sciencesMortality rateProgressive multifocal leukoencephalopathyHazard ratioPrognosis3. Good healthPathogenesis and modulation of inflammation [N4i 1]Infectious DiseasesCombinationDrug Therapy CombinationFemaleInfection and autoimmunity [NCMLS 1]HumanMicrobiology (medical)Adultmedicine.medical_specialtyPrognosiAnti-HIV Agentsantiretroviral therapyInfectious DiseaseArticleAIDS-Related Opportunistic Infection03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)Drug TherapyInternal medicinemedicineHumansAIDS-defining eventProportional Hazards ModelsAIDS-Related Opportunistic Infections/diagnosis/ mortality; Acquired Immunodeficiency Syndrome/complications/diagnosis/drug; therapy/ mortality; Adult; Anti-HIV Agents/ therapeutic use; Cohort Studies; Drug Therapy; Combination; Female; Humans; Lymphoma; AIDS-Related/diagnosis/mortality; Male; Prognosis; Proportional Hazards ModelsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic Infectionsbusiness.industryProportional hazards modelPoverty-related infectious diseases [N4i 3]Anti-HIV Agentmedicine.diseasemortalityConfidence intervalImmunologyProportional Hazards ModelCohort Studiebusiness
researchProduct